Condition Directory

Obesity clinical trials

Directory of U.S. ClinicalTrials.gov public records for Obesity. Browse Obesity recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 7, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 6, 2026, 11:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

608

Shown on this page

Current sort

How Obesity studies are organized in the registry

Obesity research spreads across several neighboring registry terms — “overweight,” “weight loss,” and “metabolic syndrome” all label closely related studies — so checking more than one term gives a fuller picture. The portfolio includes many behavioral and lifestyle studies alongside drug trials, which makes the study-type filter (interventional vs. observational) more informative than usual.

Terms that often appear in related listings

weight loss overweight metabolic syndrome bariatric

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 13–24 of 608 matching trials for Obesity.

Live ClinicalTrials.gov results.

Active filters: "metabolic syndrome" Clear condition filters

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Polycystic Ovarian Syndrome in Adolescent Females, Obesity (Disorder)
Interventions: GLP-1 Receptor Agonists; Drug
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 12 Years to 18 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Polyneuropathies, Obesity, Bariatric Surgery Candidate
Interventions: High Intensity Interval Training (HIIT), Routine Exercise, Bariatric surgery; Other · Procedure
Lead sponsor: University of Michigan; Other
Eligibility: 40 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Metabolic Syndrome, Hypertension, Overweight and Obesity
Interventions: Eplerenone, Chlorthalidone with potassium chloride; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity, Overweight, Obstructive Sleep Apnoea
Interventions: NNC0487-0111, Placebo (matched to NNC0487-0111); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 17
States / cities: San Diego, California • Miami, Florida • Naples, Florida + 13 more

Conditions: Obesity, Morbid, Metabolic Syndrome, NASH - Nonalcoholic Steatohepatitis
Interventions: 50 cm BP limb length, 100 cm BP limb length, 150 cm BP limb length; Procedure
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years to 80 Years
Enrollment: 750 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2031
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Morbid Obesity, Metabolic Syndrome, Diabetes Mellitus, Hypertension, Obstructive Sleep Apnea of Adult
Interventions: GLP-1 receptor agonist; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Polycystic Ovary Syndrome
Interventions: Mirabegron, B Complex Plus Vitamin C Tablets; Drug · Other
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Obesity, Overweight, Obstructive Sleep Apnoea
Interventions: NNC0487-0111, Placebo (matched to NNC0487-0111); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 20
States / cities: Gilbert, Arizona • Bradenton, Florida • Naples, Florida + 16 more

Conditions: Obesity, Body Weight
Interventions: DGA Mediterranean diet pattern, energy balance, DGA Mediterranean diet pattern, negative energy balance, TAD diet pattern, negative energy balance; Other
Lead sponsor: USDA, Western Human Nutrition Research Center; Federal
Eligibility: 19 Years to 64 Years · Female only
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Davis, California

Conditions: Prader-Willi Syndrome
Interventions: ARD-101; Drug
Lead sponsor: Aardvark Therapeutics, Inc.; Industry
Eligibility: 17 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Palo Alto, California • Aurora, Colorado

Conditions: Autism Spectrum Disorder (ASD), Cardiometabolic Health Indicators, Cardiometabolic Risk Factors, Metabolic Syndrome, Prediabetes
Interventions: Not listed
Lead sponsor: University of Virginia; Other
Eligibility: 6 Years to 18 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Obesity and Obesity-related Medical Conditions
Interventions: Bariatric Surgery, Semaglutide, Tirzepatide; Procedure · Drug
Lead sponsor: Ali Aminian; Other
Eligibility: 18 Years to 70 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

About this Obesity clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Obesity as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Obesity.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Obesity clinical trials

How Obesity studies are organized in the registry

Filter and sort this condition

Live official records

Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS)

Effect of Exercise and Surgical Weight Loss on Polyneuropathy

Aldosterone, the Mineralocorticoid Receptor, and Cardiovascular Disease in Obesity

AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

Biometabolic Outcomes After Weight Loss Surgery: An Individualized Approach

Impact GLP-1 Agonists Following Bariatric

The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists

AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

Metabolic and Bio-behavioral Effects of Following Recommendations in the Dietary Guidelines for Americans

A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome

This Study Will Evaluate Cardiorespiratory and Muscular Fitness to Examine Associations With Anthropometric Characteristics and Other Indicators of Cardiometabolic Risk Among Patients With or Without Autism Spectrum Disorder

Bariatric Surgery vs. Semaglutide vs. Tirzepatide

About this Obesity clinical trials directory page